The US FDA to Waive Interchangeability Standard for Insulin Biosimilars

 The US FDA to Waive Interchangeability Standard for Insulin Biosimilars

The US FDA Informs About Cybersecurity Vulnerabilities in Medical Devices with Bluetooth Low Energy

Shots:

  • Two doctors called for interchangeability requirements for biologics to be waived for insulin products under the Biologics Price Competition and Innovation Act (BPCIA) of 2009
  • The FDA guidance is a reminder that the rules of BPCIA should be carefully reinterpreted in order to maximize benefit, affordability, and access to insulin for all patients with diabetes in the US. The FDA streamlined the approval process for biosimilar insulins by removing the interchangeability requirement
  • Switching insulins to the biologic pathway means that biosimilar insulin manufacturers will have to conduct extra clinical trials to prove interchangeability with existing insulin products. The policy plays a major role in robust generic competition and ensuring access to high quality and affordable insulin

Click here to read full press release/ article | Ref: The US FDA | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post